From GlobeNewswire: 2025-04-23 09:20:00

Silexion Therapeutics Corp. announced a collaboration with Catalent to develop RNAi therapies for KRAS-driven cancers. Catalent will work on the formulation and manufacturing of Silexion’s siRNA candidate, SIL204, targeting various KRAS mutations in pancreatic, colorectal, and lung cancers. The partnership aims to optimize delivery routes and enhance therapeutic potential. Silexion plans to conduct toxicology studies in 2025 and initiate clinical trials in 2026. This collaboration is part of Silexion’s strategy to advance SIL204 into clinical development and regulatory submissions in Israel and the EU.

The partnership between Silexion Therapeutics and Catalent will focus on advancing innovative RNAi therapies for KRAS-driven cancers. Catalent’s expertise in formulation development will help optimize the delivery of SIL204, targeting a broad range of KRAS mutations. The collaboration aims to enhance stability, bioavailability, and delivery precision for SIL204, with plans to initiate clinical trials in the first half of 2026. This collaboration is part of Silexion’s comprehensive strategy to advance SIL204 through preclinical development and regulatory submissions in Israel and the EU.



Read more at GlobeNewswire: Silexion Therapeutics Announces Collaboration with Global